Clinical Trial

Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a single site, open-label, single-arm phase II study to determine feasibility, tolerability, and preliminary efficacy of neoadjuvant ADG126 and pembrolizumab in stage II or III colorectal cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-02-24.
Status change: Not Yet Recruiting → Recruiting 2025-07-22
Trial Details
NCT Number NCT06846268
Lead Sponsor National University Hospital, Singapore
Collaborators: Adagene Inc
Conditions Locally Advanced Colorectal Cancer
Enrollment 20 participants
Start Date 2025-04-14
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-07-25